Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Senseonics Holdings (NYSE: SENS) and Ascensia Diabetes Care have announced the integration of SweetSpot™ software with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This integration enables endocrinology practices partnered with SweetSpot to enhance patient care through seamless data review from the world's first and only One Year CGM system.
SweetSpot's platform combines centralized diabetes device data management with clinical support services. Their virtual team of Certified Diabetes Care and Education Specialists performs monthly CGM data reviews and coordinates with healthcare providers on treatment plans. The integration allows for personalized support between appointments and helps ensure timely treatment adjustments.
The partnership aims to improve glycemic control while offering practices automated capture of reimbursable care events. Eversense 365, developed by Senseonics and distributed by Ascensia, provides one year of accurate monitoring with minimal interruptions as the only implantable CGM available.
Senseonics Holdings (NYSE: SENS) e Ascensia Diabetes Care hanno annunciato l'integrazione del software SweetSpot™ con il sistema di monitoraggio continuo della glicemia Eversense® 365 (CGM) negli Stati Uniti. Questa integrazione consente alle pratiche di endocrinologia partner di SweetSpot di migliorare la cura dei pazienti attraverso una revisione dei dati senza soluzione di continuità dal primo e unico sistema CGM con durata di un anno al mondo.
La piattaforma di SweetSpot combina la gestione centralizzata dei dati dei dispositivi per il diabete con servizi di supporto clinico. Il loro team virtuale di Specialisti Certificati in Cura e Educazione del Diabete esegue revisioni mensili dei dati CGM e coordina con i fornitori di assistenza sanitaria i piani di trattamento. L'integrazione consente un supporto personalizzato tra gli appuntamenti e aiuta a garantire tempestivi aggiustamenti terapeutici.
La partnership mira a migliorare il controllo glicemico offrendo alle pratiche la registrazione automatizzata degli eventi di cura rimborsabili. Eversense 365, sviluppato da Senseonics e distribuito da Ascensia, fornisce un anno di monitoraggio accurato con interruzioni minime, essendo l'unico CGM impiantabile disponibile.
Senseonics Holdings (NYSE: SENS) y Ascensia Diabetes Care han anunciado la integración del software SweetSpot™ con el Sistema de Monitoreo Continuo de Glucosa Eversense® 365 (CGM) en los EE. UU. Esta integración permite a las prácticas de endocrinología asociadas con SweetSpot mejorar la atención al paciente a través de una revisión de datos fluida del primer y único sistema CGM de un año en el mundo.
La plataforma de SweetSpot combina la gestión centralizada de datos de dispositivos para diabetes con servicios de apoyo clínico. Su equipo virtual de Especialistas Certificados en Cuidado y Educación del Diabetes realiza revisiones mensuales de los datos del CGM y coordina con los proveedores de atención médica sobre los planes de tratamiento. La integración permite un apoyo personalizado entre citas y ayuda a garantizar ajustes de tratamiento oportunos.
La asociación tiene como objetivo mejorar el control glucémico mientras ofrece a las prácticas la captura automatizada de eventos de atención reembolsables. Eversense 365, desarrollado por Senseonics y distribuido por Ascensia, proporciona un año de monitoreo preciso con interrupciones mínimas, siendo el único CGM implantable disponible.
센소닉스 홀딩스 (NYSE: SENS)와 아센시아 당뇨 관리가 미국에서 Eversense® 365 지속 혈당 모니터링 (CGM) 시스템과 SweetSpot™ 소프트웨어의 통합을 발표했습니다. 이 통합은 SweetSpot과 파트너 관계를 맺고 있는 내분비학 진료소가 세계 최초이자 유일한 1년 CGM 시스템의 원활한 데이터 검토를 통해 환자 치료를 향상할 수 있도록 합니다.
SweetSpot의 플랫폼은 중앙 집중식 당뇨 기기 데이터 관리와 임상 지원 서비스를 결합합니다. 그들의 가상 팀인 인증된 당뇨 관리 및 교육 전문가들이 매월 CGM 데이터 검토를 수행하고 치료 계획에 대해 의료 제공자와 조정합니다. 이 통합은 약속 사이에 개인화된 지원을 가능하게 하며 시기 적절한 치료 조정을 보장하는 데 도움을 줍니다.
이 파트너십은 자동화된 환급 가능한 치료 이벤트 캡처를 제공하면서 혈당 조절을 개선하는 것을 목표로 하고 있습니다. 센소닉스가 개발하고 아센시아가 배급하는 Eversense 365는 최소한의 중단으로 1년 동안 정확한 모니터링을 제공하며, 유일한 이식 가능한 CGM입니다.
Senseonics Holdings (NYSE: SENS) et Ascensia Diabetes Care ont annoncé l'intégration du logiciel SweetSpot™ avec le Système de Surveillance Continue de Glucose Eversense® 365 (CGM) aux États-Unis. Cette intégration permet aux pratiques d'endocrinologie partenaires de SweetSpot d'améliorer les soins aux patients grâce à une révision des données fluide du premier et seul système CGM d'un an au monde.
La plateforme de SweetSpot combine la gestion centralisée des données des dispositifs de diabète avec des services de soutien clinique. Leur équipe virtuelle de Spécialistes Certifiés en Soins et Éducation du Diabète effectue des révisions mensuelles des données CGM et coordonne avec les prestataires de soins de santé sur les plans de traitement. L'intégration permet un soutien personnalisé entre les rendez-vous et aide à garantir des ajustements de traitement en temps opportun.
Le partenariat vise à améliorer le contrôle glycémique tout en offrant aux pratiques une capture automatisée des événements de soins remboursables. Eversense 365, développé par Senseonics et distribué par Ascensia, fournit un an de surveillance précise avec des interruptions minimales, étant le seul CGM implantable disponible.
Senseonics Holdings (NYSE: SENS) und Ascensia Diabetes Care haben die Integration der SweetSpot™-Software mit dem Eversense® 365 kontinuierlichen Glukoseüberwachungssystem (CGM) in den USA angekündigt. Diese Integration ermöglicht es den mit SweetSpot verbundenen endokrinologischen Praxen, die Patientenversorgung durch nahtlose Datenüberprüfung des weltweit ersten und einzigen CGM-Systems mit einer Laufzeit von einem Jahr zu verbessern.
Die Plattform von SweetSpot kombiniert eine zentrale Datenverwaltung für Diabetesgeräte mit klinischen Unterstützungsdiensten. Ihr virtuelles Team von zertifizierten Diabetespflege- und Bildungsspezialisten führt monatliche CGM-Datenüberprüfungen durch und koordiniert mit Gesundheitsdienstleistern über Behandlungspläne. Die Integration ermöglicht eine personalisierte Unterstützung zwischen den Terminen und hilft, rechtzeitige Anpassungen der Behandlung sicherzustellen.
Die Partnerschaft zielt darauf ab, die glykämische Kontrolle zu verbessern, während sie den Praxen die automatisierte Erfassung von erstattungsfähigen Pflegeereignissen bietet. Eversense 365, entwickelt von Senseonics und vertrieben von Ascensia, bietet ein Jahr genaue Überwachung mit minimalen Unterbrechungen und ist das einzige implantierbare CGM, das verfügbar ist.
- Integration enables new revenue streams through automated capture of reimbursable care events
- Expands market reach through partnership with endocrinology practices
- Enhances product offering with integrated data management capabilities
- None.
Insights
The strategic software integration between SweetSpot and Senseonics' Eversense 365 system represents a significant commercial development for Senseonics (NYSE: SENS) in the competitive CGM market. This partnership creates a unique value proposition by combining Eversense 365's one-year implantable CGM technology with SweetSpot's virtual monitoring platform and clinical support services.
This integration addresses two critical business challenges for Senseonics: product differentiation and market penetration. By enabling seamless data sharing with SweetSpot's platform, Senseonics enhances its competitive positioning against dominant players like Dexcom and Abbott by offering endocrinology practices a more comprehensive solution that includes both innovative hardware and supportive software infrastructure.
For endocrinology practices, this integration creates a compelling revenue opportunity through SweetSpot's automated capture of reimbursable care events. The ability to monetize monthly CGM data reviews provides financial incentives for practices to recommend Eversense 365 over competing systems, potentially accelerating adoption rates for Senseonics' technology.
Importantly, this partnership addresses a key adoption barrier for Eversense - the need for specialized insertion and removal procedures - by creating additional revenue streams for practices that offset the procedural learning curve. By integrating with established clinical workflows through SweetSpot, Senseonics makes its unique implantable technology more accessible and financially attractive to healthcare providers.
This development signals Senseonics' strategic focus on building an ecosystem around its core technology rather than competing solely on device features. By partnering with complementary software solutions, Senseonics is creating switching costs and network effects that could help defend its market position and potentially improve margins through increased utilization of its flagship product.
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world’s first and only One Year CGM system
SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care
GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This software integration provides endocrinology practices that partner with SweetSpot the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients using Eversense 365, the world's first and only One Year CGM.
SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services. SweetSpot’s virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients on treatment plan assessment and changes. By developing an integration with Eversense 365, SweetSpot can work alongside practices to act on this unique system’s CGM data in between patients’ scheduled appointments, allowing for more personalized support. These regular data reviews help ensure patients get timely treatment adjustments, keeping them better connected to their diabetes care team year-round with a goal of improving glycemic control. Practices can also unlock new opportunities through SweetSpot’s automated capture of reimbursable care events, making partnering with SweetSpot both clinically impactful and operationally efficient.
Eversense 365 is developed by Senseonics and brought to patients by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE: 6523). As the only implantable CGM available, it offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision-making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM.
Dr Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, said: “SweetSpot removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care. Our dedicated team is passionate about transforming how diabetes is managed – and making sure that no opportunities are missed to use the rich data from CGMs for improved care. This integration with Eversense reinforces SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for our partners by integrating more CGM options, such as the only implantable CGM on the market.”
Mukul Jain, Chief Operating Officer of Senseonics, added: “We are pleased to enable integration with SweetSpot to help healthcare providers using the software platform to optimize care for patients using Eversense 365. Our CGM offers a completely fresh approach to diabetes management by collecting a whole year of glucose data with just one CGM. We continue to focus on bringing Eversense 365 to more people across the country and are excited to see how integrations like this can further enhance our compelling offering for patients and healthcare providers.”
Dr. Jacob Vadakekalam of the Diabetes & Glandular Disease (DGD) Clinic in San Antonio, Texas, added: “As a doctor committed to providing the best care possible, I am pleased about the partnership between SweetSpot and Eversense. This collaboration represents a step forward in healthcare integration, and I believe it will have a positive impact on diabetes management for my patients here at the Diabetes & Glandular Disease Clinic and in turn minimizing future hospitalizations.”
Notes for Editors
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see www.eversensediabetes.com/safety-info/.
A media kit for Eversense 365, including images, logos and further information, can be accessed at www.ascensia.com/media/eversense365-media-kit/
About SweetSpot
SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care. SweetSpot combines a centralized software platform for managing diabetes device data, such as data from CGMs and insulin pumps, with wrap-around clinical support services. SweetSpot’s virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients to facilitate treatment plan changes. By actively managing and remotely reviewing CGM data between patient visits, we ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes. Additionally, SweetSpot’s automated capture of reimbursable care events optimizes CPT code utilization, unlocking new revenue streams for practices and making our partnerships both clinically effective and financially profitable.
For more information, visit www.sweetspot.health.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
Forward Looking Statements
Any statements in this press release about the expectations regarding potential impact on patients’ and providers’ experience and outcomes, and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Ascensia Communications Contact:
Tim Stamper
FTI Consulting
Tim.Stamper@fticonsulting.com
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
SweetSpot Communications Contact:
Joelle Fredman
Director of Marketing
jfredman@aegisdigitalhealth.com
FAQ
What are the key benefits of the SweetSpot and Eversense 365 CGM integration for SENS investors?
How long does the Eversense 365 CGM system by Senseonics (SENS) last?
What makes Senseonics' (SENS) Eversense 365 different from other CGM systems?
How does the SweetSpot integration affect patient care for Senseonics (SENS) users?
